Private Equity 24 Hours

Last updated: May 23, 2026, 2:30 AM ET

Private Equity Deal Flow

In the past 24 hours, private‑equity activity sharpened around high‑growth sectors and asset disposals. A consortium led by Churchill Asset Management and 50 South Capital sold the CV asset MCE to Frontenac, clearing a path for Frontenac to deepen its industrial holdings while freeing capital for new acquisitions. Meanwhile, the pain‑management niche attracted fresh capital as Charterhouse Capital, Iron Path and Revelar Capital tapped into platforms and add‑ons for the sector, underscoring the theme that medical‑device specialists remain a magnet for leveraged buyouts. In a related move, Charlesbank Capital and Nordic manufacturers merged two orthopedics producers into a focused platform, signaling a consolidation trend that could drive valuation premiums in niche medical markets.

AI and Tech Funding

The AI space continued to dominate venture financing, with the week’s top ten rounds featuring several AI‑focused deals that pushed valuations beyond traditional metrics. Tech Crunch Venture reports that some AI startups inflate ARR figures to showcase traction, a tactic investors openly accept as a shorthand for growth potential. Parallel to this, Crunchbase News lists a series of massive funding rounds that span aerospace, fintech and retail technology, illustrating that capital flows remain robust across the tech spectrum despite broader market volatility Crunchbase list. The surge in AI capital, coupled with the willingness to stretch performance metrics, may pressure future valuation models as investors seek higher upside in a competitive landscape.

Public‑Market Moves and IPOs

The consumer‑tech segment saw a notable development when Norwegian wearable‑tech company Oura filed for a New York IPO, aiming to capitalize on the growing health‑tech corridor. The filing follows a period of strong investor interest in wearables, and the company plans to use proceeds to scale production and expand its global footprint. In the life‑sciences arena, two European players moved quietly: Avista and Damier Group acquired vitamin manufacturer Sanotact, a deal that expands Damier’s portfolio in the rapidly growing nutraceutical market and positions Avista for further European expansion.

Strategic Shift in Portfolio Focus

Partners Group’s Todd Miller highlighted a strategic pivot toward mature, yield‑oriented assets, stating that the firm identified a “white space” in corporate PE for a total‑return strategy Partners Group interview. This shift reflects a broader industry trend where fund managers balance high‑growth tech bets with stable, income‑producing sectors, especially as interest rates remain elevated. Together, these moves illustrate a diversified approach that blends aggressive growth playbooks with conservative income generation, a duality that private‑equity firms will likely continue to navigate